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ABSTRACT:
We report herein the identification of a novel metabolic pathway
that involves acetylation of the amino group of the glutamic acid
residue of intact glutathione (GSH) conjugates of a series of com-
pounds in rat hepatocytes and in rats in vivo. The “nonacetylated”
as well as the “acetylated” GSH conjugates of the compounds in
question were detected in rat hepatocyte incubations and in rat
bile. These conjugates were characterized by online liquid chro-
matography-mass spectrometry on an ion-trap mass spectrome-
ter as well as accurate mass measurements using a high-resolu-
tion quadrupole time-of-flight instrument. The accurate mass
measurements on the molecular ions of nonacetylated and acety-
lated GSH adducts clearly revealed the addition of a mass equiv-
alent to C2H2O in the latter conjugates. Furthermore, the collision-
induced dissociation of the molecular ions of nonacetylated GSH
adducts yielded fragment ions involving the loss of pyroglutamate
(129 Da), which are typical of many GSH conjugates. For acetylated
adducts, however, fragment ions resulting from a loss of 171 Da
(equivalent to N-acetyl-pyroglutamate) were observed, indicating
that acetylation had occurred on the glutamic acid residue of the
GSH conjugates. An enzyme-catalyzed transacetylation process
that utilized acetyl CoA as the acetyl donor, and resulted in the
formation of the same acetylated adducts that were detected in rat
hepatocytes and in rat bile, was identified in rat liver microsomes.
This appears to be the first reported instance of N-acetylation of
intact GSH conjugates in any species and represents a novel path-
way of metabolic processing of thiol adducts of xenobiotics.
Glutathione (GSH1) conjugation is a prominent pathway of metab-
olism for many xenobiotics, especially the ones that are bioactivated
to reactive electrophilic intermediates via oxidative metabolism (Par-
kinson, 2001). The GSH conjugates may either be excreted intact in
bile or may undergo further processing via the so called “mercapturic
acid pathway”. The latter involves sequential cleavage of the glutamic
acid and glycine residues of the GSH moiety via the enzymes -glu-
tamyl transpeptidase (to form cysteinylglycine-S-conjugates) and ami-
nopeptidase-M (to form cysteine-S-conjugates), respectively (Com-
mandeur et al., 1995; Parkinson, 2001). This processing of GSH
conjugates is believed to occur in the kidney because of a high activity
of the above enzymes in this tissue. The resulting cysteine S-conju-
gates are then N-acetylated at the cysteine amino group via the
cysteine S-conjugate N-acetyltransferase to form N-acetyl cysteine or
mercapturic acid metabolites (Commandeur et al., 1995). This N-
acetylation reaction can occur in the kidney itself or the cysteine
S-conjugates may be transported back to the liver and acetylated in
that tissue; the resulting mercapturic acid metabolites, however, are
almost always excreted in urine (Inoue et al., 1982, 1984; Comman-
deur et al., 1995). Some recent studies have suggested the presence of
at least one alternate pathway for the metabolic processing of GSH
conjugates of xenobiotics. This pathway involves the conjugation of
GSH, cysteinylglycine-, and cysteine S-conjugates with the -carbox-
ylic acid moiety of glutamic acid to form extended peptide conjugates
(Mutlib et al., 2000, 2002). Herein we describe the identification of
another novel pathway for the metabolic processing of thiol adducts in
rats that involves the N-acetylation of the glutamic acid residue of
intact GSH conjugates.
Materials and Methods
Materials. Compounds 1 to 3 (Fig. 1) were synthesized within the
Department of Medicinal Chemistry, Merck Research Laboratories
(Rahway, NJ). A tritiated analog of 1 (specific activity 37 mCi/mg,
purity 98.5%) was synthesized by Labeled Compound Synthesis,
Department of Drug Metabolism, Merck Research Laboratories. A
protein assay reagent kit was purchased from Pierce Chemical (Rock-
ford, IL). All other chemicals were purchased from Sigma-Aldrich
(St. Louis, IL) and were of reagent grade. All animal procedures
performed were approved by the Merck Research Laboratories Insti-
tutional Animal Care and Use Committee.
Incubations with Rat Hepatocytes. Hepatocytes were isolated from the
perfusion of the whole male rat liver using a two-step perfusion procedure
(Pang et al., 1997). After isolation, hepatocyte preparations that exhibited a
viability of 80%, as determined by trypan blue exclusion, were suspended in
Krebs-Ringer bicarbonate buffer (pH 7.4).
For hepatocyte incubations, compounds 1 to 3 (10 M) were incubated at
37°C for 2 h with 4 ml of a freshly isolated hepatocyte suspension containing
1 Abbreviations used are: GSH, glutathione; LC, liquid chromatography; MS,
mass spectrometry; HPLC, high-performance liquid chromatography; CID, colli-
sion-induced dissociation; Q-Tof, quadrupole time-of-flight; amu, atomic mass
unit(s); XIC, extracted ion chromatogram.
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one million cells/ml in Krebs-Ringer bicarbonate buffer. Incubations were
conducted in stoppered flasks and were aerated with a 5% CO2/95% O2 gas
mixture at hourly intervals. At the end of the 2-h period, reactions were
quenched by addition of 4 ml of acetonitrile, and samples were centrifuged to
separate the precipitated residue. Supernatants were concentrated by evapora-
tion under nitrogen before analysis by LC-MSn using an ion trap mass
spectrometer.
In Vivo Metabolism Studies in Rats. Male Sprague-Dawley rats (n  3)
were anesthetized with sodium pentobarbital (Nembutal), and their femoral
veins and bile ducts were cannulated with PE-10 tubing. Animals were allowed
to recover for at least 48 h before experimentation. On the day of the
experiment, rats were placed in metabolism cages, and pretreatment bile and
urine samples were collected. Doses of 1 were prepared in an ethanol/PEG
400/water (2:2:6) solvent mixture. 1 was administered to rats intravenously via
the femoral vein (2 mg/kg, 100 Ci/kg). Cumulative bile and urine samples
were collected into tared containers at predetermined intervals for up to 72 h
after dosing and frozen at 20°C before analysis. Radioactivity concentrations
in bile and urine samples were measured using liquid scintillation counting.
Bile samples were extracted with acetonitrile and concentrated via evaporation
under nitrogen before LC-MSn analysis.
Incubations with Rat Liver Microsomes. Male rat liver microsomes were
prepared by standard differential centrifugation procedures (Raucy and Lasker,
1991). Livers from 40 naive male rats were pooled for microsome preparation.
Microsomal protein concentrations were measured according to the manufac-
turer’s instructions for the use of the protein assay kit.
1 (10 M) was incubated at 37°C with rat liver microsomes (2 mg/ml
protein) in 100 mM potassium phosphate buffer (pH 7.4) containing 10 mM
magnesium chloride and an NADPH-regenerating system consisting of glu-
cose 6-phosphate (10 mM), NADP (1 mM), and glucuose-6-phosphate de-
hydrogenase (0.7 unit/ml). All microsomal incubations were also supple-
mented with 5-mM GSH. Reactions were started by the addition of the
substrate and incubations were carried out for 2 h. To examine the acetylation
of GSH conjugates formed in the above microsomal incubations, acetyl CoA
(1 mM) was added to some incubations in the beginning and at the end of 1 h.
Negative control incubations proceeded without the addition of acetyl CoA.
Incubations without the NADPH-regenerating system were also conducted to
serve as additional negative controls. Furthermore, to demonstrate that the
observed acetylation of intact GSH conjugates is catalyzed by a microsomal
enzyme, 1 (10 M) was incubated with rat liver microsomes in the presence
of an NADPH-regenerating system and 5 mM GSH for 2 h, and the incubates
were filtered using 12,000 mol. wt. cutoff filters to remove the microsomal
material. The filtered incubates containing the in situ generated GSH adducts
of 1 were then incubated with acetyl CoA (1 mM) in the presence or absence
of rat liver microsomes (2 mg/ml protein) for an additional 2 h. Negative
control incubations included acetyl CoA either with or without boiled rat liver
microsomes. To determine the subcellular localization of enzyme(s) catalyzing
the acetylation of GSH conjugates, parallel incubations also were carried out
in the presence of rat liver cytosol (2 mg/ml protein). At the end of the
incubation time, the reactions were quenched with 2 ml of acetonitrile. Sam-
ples were vortex mixed, refrigerated to precipitate the protein, and centrifuged
at 3000g for 15 min. The supernatant was concentrated by evaporation under
nitrogen before analysis by LC-MSn.
LC-MSn Analysis. Chromatographic separation of metabolites was
achieved on a Phenomenex Synergi Polar RP-80A reverse-phase HPLC col-
umn (25 cm  4.6 mm, 4 m; Phenomenex, Torrance, CA) using two PE
Series 200 pumps and a PE Series 200 auto-injector (PerkinElmer Life and
Analytical Sciences, Inc., Boston, MA). Mobile phase A consisted of 5 mM
ammonium acetate and mobile phase B of a 70:30 acetonitrile/methanol
mixture. Both mobile phases contained 0.1% formic acid. Metabolites of
interest were eluted using a gradient profile in which the HPLC run began with
30% solvent B for the first 2 min, which was increased to 40% at 40 min, and
then to 90% at 50 min using linear gradients. Solvent composition was held at
90% B until 60 min to flush the column before re-equilibration. Flow rate was
1 ml/min and the column effluent was split 1:5 between the mass spectrometer
and the online radioactivity detector, respectively. Radioactivity detection was
performed using an online radioactivity detector (-RAM; IN/US Systems,
Tampa, FL). The structural identification of metabolites was performed using
a Finnigan LCQ DECA XP Ion Trap Mass Spectrometer (Thermo Finnigan,
San Jose, CA) operated in positive ion electrospray mode. The spray voltage
was set at 4.5 kV and the sample transfer tube temperature at 300°C. The mass
spectrometer was operated in the data-dependent acquisition scan mode to
simultaneously acquire full scan MS and MSn (generally only up to MS2) data.
The relative collision energy for CID experiments was set at 45%.
Accurate Mass Measurements using a Q-Tof II Mass Spectrometer. The
Q-Tof II mass spectrometer (Micromass, Inc., Cheshire, UK) had a minimum
mass resolution of 6000 [measured as full width at half-maximum (FWHM)]
during all experiments. The mass spectrometer was operated in positive ion
electrospray mode and was calibrated on each experiment day using a mixture
solution of polyethylene glycols with known exact molecular masses (approx-
imate range 100-1000 Da). Electrospray capillary voltage and cone voltage
were set at 3400 V and 40 V, respectively. Source and desolvation tempera-
tures were 100 and 300°C, respectively. Nitrogen was used as the desolvation
and nebulizing gas at flow rates of 400 and 50 l/h, respectively. Full scan Tof
MS spectra were acquired for measurement of accurate masses of molecular
ions of parent compounds and relevant metabolites. Chromatographic condi-
tions were the same as those used for the LC-MSn experiments described
above, except that a Hewlett-Packard Series 1100 HPLC system (Hewlett
Packard, Palo Alto, CA) consisting of two pumps, an autosampler, and a
column oven was utilized. Leucine-enkephalin (1 g/ml) was introduced into
the column effluent at a rate of 5 l/min via a T-joint to act as an internal mass
calibrant (lock-mass). Acquisition and analysis of the data were performed
using MassLynx software (version 3.5, Micromass Inc.).
Results and Discussion
At least three different groups of GSH adducts, with molecular ions
at m/z 862, 860, and 904, were detected upon incubation of 1 with rat
hepatocytes (Fig. 2). Figure 3 shows the MS2 mass spectra obtained
using CID of molecular ions of these three groups of GSH adducts, as
well as the relevant fragment ion assignments; the spectra of the two
adducts within each group were identical. The mass of the molecular
ion of GS1a and GS1b suggests an addition of 305 Da to the mass of
1, which corresponds to the addition of one GSH molecule. The MS2
spectrum of adducts GS1a and GS1b (Fig. 3A) shows a characteristic
loss of 129 amu (corresponding to the pyroglutamate residue of the
added GSH moiety; Baillie and Davis, 1993) to form an ion at m/z
733, which is consistent with this metabolite being a GSH adduct. The
fragment ions at m/z 533 and 589 apparently correspond to the
cleavage of the C–S bond of the cysteine residue either with or
without the concurrent loss of the t-butyl moiety, thus leaving a free
thiol substituent on the core structure of 1. All of these GSH adducts
were formed in trace amounts only in rat hepatocyte incubations, and
therefore, it was not possible to isolate these in enough quantities for
determination of exact regio-chemistry of GSH addition using NMR.
However, we have evidence from our work on some other close
FIG. 1. Structures of the five compounds discussed in the text.
 denotes the position of the tritium label in the radiolabeled analog of 1.
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analogs of 1 that the “bottom” halo-substituted aryl ring is the site of
bioactivation and GSH addition for these compounds (also see below).
The m/z of the molecular ion of adducts GS2a and GS2b indicates
an addition of 303 Da to the mass of 1. Such adducts typically result
from a mechanism involving epoxidation of the aromatic ring adjacent
to the fluorine substitution, followed by the addition of GSH and loss
of HF, such that the original fluorine subsituent is replaced with an
-OH moiety (Fig. 5; Park et al., 2001; Parkinson, 2001; Samuel et al.,
2003). The MS2 spectrum of GS2a and GS2b (Fig. 3B) is very similar
to that seen for GS1a and GS1b except for the 2-amu difference in all
fragment ions involving the core structure of 1. This is consistent with
the replacement of fluorine substitution with an OH moiety in the
GS2a and GS2b structure and provides additional evidence that the
“bottom” aryl ring of 1 is the site of bioactivation and GSH addition
in rat hepatocytes.
The nominal mass of the molecular ions of adducts GS3a and GS3b
indicates the addition of 347 Da to the mass of 1, which can be
interpreted as the addition of one GSH (305 Da) and one acetyl (42
Da) moiety. To further substantiate this interpretation, accurate mass
measurements were performed on the molecular ions of the parent
compound 1, GS1a and GS1b, and GS3a and GS3b adducts using a
high-resolution Q-Tof II mass spectrometer. The accurate mass data,
the suggested elemental composition, and deviations of the measured
mass from the theoretically calculated mass are presented in Table 1.
The small deviations (5 ppm) observed in all cases lend support to
the suggested elemental composition presented in Table 1 for these
compounds. The indicated elemental composition of GS1a and GS1b
is consistent with these being the products of addition of one molecule
of GSH to the parent 1. Furthermore, the comparison of the suggested
elemental compositions of GS1a and GS1b versus GS3a and GS3b
suggests a difference in mass corresponding to C2H2O (Table 1); this
supports the interpretation that GS3a and GS3b represent acetylated
analogs of GS1a and GS1b or regio-isomers thereof. Interestingly, the
MS2 fragmentation of GS3a and GS3b involved a characteristic loss
of 171 amu (instead of 129 in GS1a and GS1b) to form the same
fragment ion that was observed for GS1a and GS1b at m/z 733 (Fig.
3C). This indicates that the acetylation has occurred on the amino
group of the glutamate residue of the adduct (Fig. 3C). Many other
fragment ions observed in the MS2 spectrum of GS3a and GS3b were
similar to those observed for GS1a and GS1b and support the inter-
pretation that the core structure of 1 was unaltered in these adducts.
Similar adducts were observed for compounds 2 and 3 also upon
incubation with rat hepatocytes, and their MS2 spectra as well as
accurate mass measurements were in line with the observations made
for compound 1 above (data not shown).
When a 2 mg/kg dose of [3H]1 was administered intravenously to
FIG. 2. Extracted ion chromatograms (XIC) of GSH adducts of 1 detected in rat hepatocyte incubations.
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bile duct-cannulated rats, 65% of the administered radioactivity was
recovered in bile within 72 h after dosing. Of that 65%, a pyridinium
metabolite formed via aromatization of the t-butyl piperidine, and
glucuronic acid conjugates of multiple hydroxylated metabolites of 1
accounted for 75% and were the major components. In addition,
small amounts of the parent compound (5%) and unconjugated mono-
(5%) and dihydroxylated metabolites (5%) were also present. All
three groups of GSH adducts detected in rat hepatocyte incubations
were identified in rat bile as well and collectively accounted for
10% of the total radioactivity excreted in bile. The composition of
the remaining 35% of the radioactivity that was not recovered during
the course of these studies remains unknown. These data indicate that
the novel pathway that leads to the N-acetylation of intact GSH
adducts at the glutamic acid residue is operational in rats in vivo as
well as in vitro.
The GSH adducts GS1a and GS1b of 1 identified above in rat
hepatocyte incubations and in rat bile were also formed in rat liver
microsomal incubations that were supplemented with 5 mM GSH,
although the relative proportions of the two isomers were somewhat
different relative to those observed in hepatocytes and in rat bile (Fig.
4A, upper panel). As expected, however, their corresponding acety-
FIG. 3. MS2 spectra of GSH adducts of 1 with molecular ions at m/z 862 (GS1a and GS1b) (A), m/z 860 (GS2a and GS2b) (B), and m/z 904 (GS3a and GS3b) (C)
that were detected in rat hepatocyte incubations.
The exact regio-chemistry of GSH addition on the molecule is not known, and the structures drawn are for illustration only. These same adducts were detected in rat
bile after [3H]1 administration as well.
TABLE 1
Accurate masses of the molecular ions (MH) of the GSH- and N-acetyl-GSH
adducts of 1 in rat hepatocytes
Accurate mass measurements were obtained using high-resolution time of flight mass
spectrometry on a Q-Tof II mass spectrometer. The suggested elemental composition and
deviations from the calculated masses are also presented.








1 Parent 557.1309 C30H29N2OFCl3
 2.0 3.6
GS1a and GS1b 862.1981 C40H44N5O7FSCl3
 3.0 3.5
GS3a and GS3b 904.2139 C42H46N5O8FSCl3
 2.2 2.4
mDa, milli-Daltons.
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lated analogs GS3a and GS3b were not present in these incubations
(Fig. 4A, lower panel). Interestingly, when 1 mM acetyl CoA was
added to these microsomal incubations, GS3a and GS3b were readily
detectable (Fig. 4B, lower panel). These data indicate that acetyl CoA
acts as an acetyl donor for the acetylation of GS1a and GS1b to GS3a
and/or GS3b in rat liver microsomal incubations (Fig. 5). When rat
liver microsomal incubates of 1 containing GS1a and GS1b were
filtered to remove the microsomal material and were further incubated
with acetyl CoA in the presence or absence of active rat liver micro-
somes, boiled rat liver microsomes, or rat liver cytosol, the acetylated
FIG. 4. Extracted ion chromatograms (XIC) of GSH adducts of 1 in rat liver microsomal incubations conducted either in the absence (A) or presence (B) of 1 mM
acetyl CoA and supplemented with 5 mM GSH.
The upper panel is XIC at m/z 862 (corresponding to GS1a and 1b) and the lower panel is at m/z 904 (corresponding to GS3a and 3b) in both A and B.
FIG. 5. Postulated mechanisms for the formation of various GSH adducts of 1 that were identified in rat hepatocyte incubations and in rat bile.
The exact regio-chemistry of GSH addition in these adducts is unknown, and multiple other regio-isomers are possible. The drawn structures are for illustrative purposes
only.
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conjugates GS3a and GS3b were detected only in incubations con-
taining active rat liver microsomes. Thus, the transacetylation of GS1a
and GS1b to GS3a and GS3b appears to be catalyzed by an enzyme
present in rat liver microsomes. The identity of the enzyme(s) cata-
lyzing this novel transacetylation reaction remains to be determined.
Previous studies indicate that cysteine S-conjugate N-acetyltrans-
ferase, which is responsible for the acetylation of cysteine S-conju-
gates to the corresponding mercapturic acids (N-acetyl cysteine con-
jugates), is also a microsomal enzyme, with its active site located
toward the cytoplasmic surface, and the highest activities of this
enzyme are present in the liver and the kidney (Okajima et al., 1984;
Commandeur et al., 1995). It is possible that either the same enzyme
or a closely related member of the same family is responsible for the
acetylation of intact GSH adducts at the glutamic acid residue, as
observed in the current studies.
To our knowledge this is the first reported instance of the acetylation
of intact GSH adducts of xenobiotics in any species. This metabolic route,
in combination with the recently discovered “glutamic acid pathway” that
results in the formation of extended peptide adducts (Mutlib et al., 2000,
2002), represents examples of alternate metabolic processes for the han-
dling of xenobiotic-GSH conjugates relative to the more common mer-
capturic acid pathway. The biological significance of these pathways of
processing of GSH conjugates, and whether these metabolic processes
exist in species other than the rat, is not known at present. Furthermore,
it remains to be determined whether these “acetylated” GSH conjugates
can serve as substrates for -glutamyl transpeptidase and be converted to
the corresponding cysteinyl-glycine conjugates, as is known to occur for
numerous other “nonacetylated” GSH adducts. It appears, however, that
multiple routes are likely available for the sequential processing of thiol
conjugates of xenobiotics in mammalian species, and these will continue
to be discovered with recent innovations in sophisticated analytical meth-
odologies.
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